Analysts expect Baxter International Inc (NYSE:BAX) to report sales of $2.79 billion for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Baxter International’s earnings, with the highest sales estimate coming in at $2.79 billion and the lowest estimate coming in at $2.78 billion. Baxter International posted sales of $2.71 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 3%. The company is expected to report its next earnings report before the market opens on Wednesday, October 31st.

On average, analysts expect that Baxter International will report full year sales of $11.20 billion for the current fiscal year, with estimates ranging from $11.18 billion to $11.26 billion. For the next year, analysts expect that the firm will report sales of $11.68 billion, with estimates ranging from $11.54 billion to $11.84 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Baxter International.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, July 26th. The medical instruments supplier reported $0.77 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.06. The firm had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.83 billion. Baxter International had a net margin of 8.29% and a return on equity of 16.63%. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.63 EPS.

BAX has been the topic of several analyst reports. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a report on Tuesday. Royal Bank of Canada reissued a “hold” rating and issued a $76.00 price target on shares of Baxter International in a report on Friday, July 27th. Argus reissued a “hold” rating on shares of Baxter International in a report on Tuesday, September 4th. Citigroup boosted their price target on shares of Baxter International from $74.00 to $76.00 and gave the company a “neutral” rating in a report on Tuesday, July 31st. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $77.00 price target on shares of Baxter International in a report on Thursday, May 31st. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Baxter International has a consensus rating of “Buy” and a consensus target price of $76.43.

Baxter International stock traded down $0.30 on Monday, hitting $76.60. The company’s stock had a trading volume of 2,181,900 shares, compared to its average volume of 3,021,469. The firm has a market capitalization of $41.38 billion, a PE ratio of 30.89, a price-to-earnings-growth ratio of 2.09 and a beta of 0.74. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.62 and a quick ratio of 2.00. Baxter International has a one year low of $60.78 and a one year high of $78.38.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 1st. Stockholders of record on Friday, August 31st will be paid a $0.19 dividend. The ex-dividend date of this dividend is Thursday, August 30th. This represents a $0.76 annualized dividend and a dividend yield of 0.99%. Baxter International’s dividend payout ratio is presently 30.65%.

In other news, Director Carole J. Shapazian sold 5,400 shares of the business’s stock in a transaction on Wednesday, August 8th. The shares were sold at an average price of $72.97, for a total value of $394,038.00. Following the sale, the director now owns 15,248 shares in the company, valued at approximately $1,112,646.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Scott Pleau sold 10,686 shares of the business’s stock in a transaction on Tuesday, July 10th. The shares were sold at an average price of $75.00, for a total transaction of $801,450.00. Following the completion of the sale, the senior vice president now owns 26,349 shares in the company, valued at approximately $1,976,175. The disclosure for this sale can be found here. Insiders sold a total of 33,733 shares of company stock worth $2,559,072 in the last 90 days. 0.05% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of the company. United Services Automobile Association lifted its position in Baxter International by 0.3% during the 2nd quarter. United Services Automobile Association now owns 354,917 shares of the medical instruments supplier’s stock worth $26,207,000 after buying an additional 1,087 shares in the last quarter. Rehmann Capital Advisory Group lifted its position in Baxter International by 231.7% during the 2nd quarter. Rehmann Capital Advisory Group now owns 6,014 shares of the medical instruments supplier’s stock worth $444,000 after buying an additional 4,201 shares in the last quarter. Royal London Asset Management Ltd. acquired a new position in Baxter International during the 2nd quarter worth about $15,475,000. Schroder Investment Management Group lifted its position in Baxter International by 105.5% during the 2nd quarter. Schroder Investment Management Group now owns 4,674 shares of the medical instruments supplier’s stock worth $345,000 after buying an additional 2,400 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its position in Baxter International by 44.2% during the 2nd quarter. Advisors Asset Management Inc. now owns 15,750 shares of the medical instruments supplier’s stock worth $1,163,000 after buying an additional 4,824 shares in the last quarter. Institutional investors own 83.04% of the company’s stock.

About Baxter International

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Read More: Technical Analysis of Stocks and What It Means

Get a free copy of the Zacks research report on Baxter International (BAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.